Efficacy of Tegoprazan in Patients With Functional Dyspepsia: A Prospective, Multicenter, Single-arm Study
- Author:
Cheal Wung HUH
1
;
Young Hoon YOUN
;
Da Hyun JUNG
;
Ra Ri CHA
;
Yeon Ji KIM
;
Kyoungwon JUNG
;
Kyung Ho SONG
;
Ki Bae BANG
;
Chung Hyun TAE
;
Soo In CHOI
;
Cheol Min SHIN
;
Author Information
- Publication Type:Original Article
- From:Journal of Neurogastroenterology and Motility 2024;30(3):313-321
- CountryRepublic of Korea
- Language:EN
-
Abstract:
Background/Aims:Acid-suppressive drugs, such as proton pump inhibitors (PPIs), are treatment options for functional dyspepsia (FD). However, the efficacy of potassium-competitive acid blockers (P-CABs) in treating FD has not yet been established. This prospective multicenter clinical trial-based study aimed to assess the efficacy and safety of tegoprazan as a P-CAB treatment in patients with FD.
Methods:FD was diagnosed using the Rome IV criteria. All patients received tegoprazan 50 mg once daily for 8 weeks. Dyspeptic symptoms were assessed using a dyspepsia symptom questionnaire (5-point Likert scale, Nepean Dyspepsia Index-Korean [NDI-K], and gastroesophageal reflux disease–health-related quality of life [GERD-HRQL]). The main outcome was satisfactory symptom relief rates at 8 weeks.
Results:In this study, from the initial screening of 209 patients, 173 were included in the per-protocol set analysis. Satisfactory symptom relief rates at 8 and 4 weeks were 86.7% and 74.6%, respectively. In addition, the NDI-K and GERD-HRQL scores significantly improved at 8 and 4 weeks compared with the baseline scores. The efficacy of tegoprazan was not influenced by the FD subtype or Helicobacter pylori status. In patients with overlapping FD and GERD, there was a greater improvement in the NDI-K and GERD-HRQL scores than in patients with FD symptoms only. No serious drug-related adverse events occurred during this study.
Conclusion:Tegoprazan (50 mg) administered once daily provided satisfactory symptom relief for FD.
